Patient P-03252
Therapy response
Improving
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
42%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S13
- Day 118 SC-12 recommended — Supportive Compound SC-12
- Day 119 Patient accepted — Started SC-12 in the companion
- Day 125 GI symptom burden −17% vs expected — Supportive Compound SC-12
- Day 131 Tolerance state changed — Unstable → Improving
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability+20
- Inflammatory activity+5
- Treatment adherence-4
- Toxicity-4
- Nutritional resilience-3
What helped?
- Supportive Compound SC-12Day 118Result: symptom burden −17%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log5.2/10
worsening · -0.4 vs previous 14 d
Stress level
Daily log5/10
worsening · +0.2 vs previous 14 d
Pessimism score
Daily log3.9/10
stable · +0.1 vs previous 14 d
Sleep quality
Wearable18.8/100
worsening · -4.8 vs previous 14 d
Libido
Daily log4.6/10
worsening · -0.4 vs previous 14 d
HRV
Wearable51.2 ms
worsening · -3.0 vs previous 14 d
Toxicity
Blood16.8/100
worsening · +6.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 71 from the failing basin, 17 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -5.4 next day on high-intake days · n 22
Would not help
- Keep lactose lowGI +4.7 next day on high-intake days · n 16
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.4supporter · 95%
- Lactose+4.7detractor · 95%
- Caffeine+2.1no signal · 46%
- Dietary fat load-1.7no signal · 37%
- Histamine load+1.5no signal · 29%
- Alcohol-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↓20
- WearableShort sleep window
- Mucosal barrier integrity ↓10
- WearableSleep 5.2 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.2 · butyrate capacity 59/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 51 ms
- Sleep
- 6.0 h
- Steps
- 7,001
- Resting HR
- 66 bpm
Daily log: GI score 31, nutritional resilience 64, adherence 96.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.